Kalbe Farma 9M26 prescription pharmaceuticals gross profit margin falls 4 percentage points to 46.4%

Bitget2026/10/30 09:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kalbe Farma's net sales rose 12% to IDR 29 trillion in 9M26, with organic growth driven by volume.
Prescription pharmaceuticals' gross profit margin fell to 46.4% from 50.4% due to raw materials and product mix.
Consumer health net sales climbed 10% to IDR 3.95 trillion.
The company is expanding its insulin and cell-therapy businesses while strengthening its vaccine portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Kalbe Farma Tbk published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kalbe Farma 9M26 prescription pharmaceuticals gross profit margin falls 4 percentage points to 46.4%

You may also like

Crypto prices